- The US Food and Drug Administration (FDA) has granted Fast Track designation to the development TRAKON‘s TCON Lead asset Envafolimab (KN035) for patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior chemotherapies. TRACON shares traded up 5.26 percent in a range of $1.9 to $2 on daily volume of 111.77 thousand shares and closed the regular trading session at $1.9.
- Centessa Pharmaceuticals CNTA announced that the US Food and Drug Administration (FDA) has granted SerpinPC orphan drug designation for the treatment of hemophilia B. Centessa shares traded up 10.56 percent in a range of $4.09 to $4.71 on daily volume of 180.95 thousand shares, closing regular trading session at $4.64.
- Eloxx Pharma ELOX announced top-line results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in patients with Class 1 cystic fibrosis (CF) with at least one nonsense mutation. The combination study was well tolerated but failed to reach statistical significance for the efficacy endpoints. Eloxx shares traded up 10.53 percent in a range of $0.38 to $0.42 on daily volume of 275.93k shares and closed the regular trading session at $0.38. The company’s shares traded at $0.19, down 50 percent in the after-hours trading session.
- Adverum Biotechnologies ADVM treated the first subject in the Phase 2 LUNA study evaluating Ixoberogen Soroparvovec (Ixo-vec, formerly known as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD). Adverum shares traded up 7.55 percent in a range of $1.06 to $1.14 on daily volume of 439,060,000 shares and closed the regular trading session at $1.09.
- Pfizer PFE announced that the first participants in a pivotal Phase 3 clinical trial evaluating the efficacy, safety, tolerability and immunogenicity of tetravalent modified RNA (modRNA) influenza have been treated…
